2.73
전일 마감가:
$2.47
열려 있는:
$2.43
하루 거래량:
3.62M
Relative Volume:
1.83
시가총액:
$200.88M
수익:
-
순이익/손실:
$-217.44M
주가수익비율:
-1.2581
EPS:
-2.17
순현금흐름:
$-205.20M
1주 성능:
+10.98%
1개월 성능:
+131.36%
6개월 성능:
-6.51%
1년 성능:
-50.18%
Prime Medicine Inc Stock (PRME) Company Profile
명칭
Prime Medicine Inc
전화
617-465-0013
주소
60 FIRST ST., CAMBRIDGE
PRME을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
PRME
Prime Medicine Inc
|
2.73 | 200.88M | 0 | -217.44M | -205.20M | -2.17 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
452.16 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
534.91 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
322.06 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
542.47 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
245.16 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Prime Medicine Inc Stock (PRME) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-05-27 | 다운그레이드 | Citigroup | Buy → Neutral |
2025-05-20 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
2025-05-20 | 다운그레이드 | JP Morgan | Overweight → Neutral |
2024-12-10 | 개시 | JMP Securities | Mkt Outperform |
2024-05-20 | 개시 | H.C. Wainwright | Buy |
2024-05-16 | 업그레이드 | Citigroup | Neutral → Buy |
2024-04-22 | 개시 | Chardan Capital Markets | Buy |
2024-04-08 | 개시 | TD Cowen | Buy |
2024-04-03 | 개시 | Wedbush | Outperform |
2024-01-16 | 다운그레이드 | Stifel | Buy → Hold |
2023-12-08 | 개시 | Citigroup | Neutral |
2023-10-09 | 개시 | BMO Capital Markets | Outperform |
2023-07-31 | 개시 | Guggenheim | Buy |
2023-04-18 | 개시 | Stifel | Buy |
2022-11-14 | 개시 | Goldman | Neutral |
2022-11-14 | 개시 | JP Morgan | Overweight |
2022-11-14 | 개시 | Jefferies | Buy |
2022-11-14 | 개시 | Morgan Stanley | Equal-Weight |
모두보기
Prime Medicine Inc 주식(PRME)의 최신 뉴스
Prime Medicine’s SWOT analysis: gene editing firm faces cash crunch amid promising tech - Investing.com
Prime Medicine’s Technological Edge and Strategic Positioning Highlighted as Key Investment Opportunity - TipRanks
Prime Medicine, Inc. (NYSE:PRME) Major Shareholder Acquires $33,600.00 in Stock - MarketBeat
Citi Downgrades Prime Medicine (PRME) to Neutral, Cuts PT to $1.50 Due to Market Uncertainty - MSN
Two Sigma Advisers LP Sells 76,700 Shares of Prime Medicine, Inc. (NYSE:PRME) - Defense World
Prime Medicine, Inc. (NYSE:PRME) Receives $10.08 Average PT from Brokerages - Defense World
Prime Medicine stock plummets amid restructuring and leadership changes - MSN
Bank of America Corp DE Trims Stock Holdings in Prime Medicine, Inc. (NYSE:PRME) - Defense World
Layoff Tracker: Capsida Downsizes as Part of Shift to Clinical-Stage Company - BioSpace
Prime Medicine Elects Directors at Annual Meeting - TipRanks
20,096 Shares in Prime Medicine, Inc. (NYSE:PRME) Bought by BNP Paribas Financial Markets - Defense World
Jane Street Group LLC Boosts Stock Position in Prime Medicine, Inc. (NYSE:PRME) - Defense World
Deutsche Bank AG Cuts Position in Prime Medicine, Inc. (NYSE:PRME) - Defense World
Altria, Prime Medicine, US Steel, DLocal, Prothena: Trending by Analysts - TipRanks
Prime Medicine Announces Key Presentations at Two Major Healthcare Investor Conferences in June - Stock Titan
Prime Medicine to Participate in Upcoming Investor Conferences - The Manila Times
Prime Medicine’s (PRME) Neutral Rating Reaffirmed at Citigroup - Defense World
Citigroup Downgrades Prime Medicine (PRME) Amid Significant Pric - GuruFocus
Prime Medicine’s SWOT analysis: gene editing firm shifts focus, stock faces challenges By Investing.com - Investing.com South Africa
Citigroup Downgrades Prime Medicine to Neutral From Buy, Adjusts Price Target to $1.50 From $10 - marketscreener.com
Prime Medicine’s SWOT analysis: gene editing firm shifts focus, stock faces challenges - Investing.com Canada
Prime Medicine (PRME) Downgraded by Citi with Reduced Price Targ - GuruFocus
Prime Medicine (PRME) Downgraded by Citi with Reduced Price Target | PRME Stock News - GuruFocus
Prime Medicine downgraded to Neutral from Buy at Citi - TipRanks
Hold Rating for Prime Medicine, Inc. Amid Financial Uncertainties and Strategic Adjustments - TipRanks
Prime Medicine (NYSE:PRME) Earns "Neutral" Rating from JPMorgan Chase & Co. - MarketBeat
Prime Medicine FY2025 EPS Estimate Raised by Chardan Capital - Defense World
Hold Rating on Prime Medicine, Inc. Amid Strategic Shifts and Financial Reevaluation - TipRanks
Critical Analysis: Prime Medicine (NYSE:PRME) and Vigil Neuroscience (NASDAQ:VIGL) - Defense World
Prime Medicine Executives Make Bold Stock Purchases! - TipRanks
Insider Buying: Ann Lee Acquires 100,000 Shares of Prime Medicine Inc (PRME) - GuruFocus
Prime Medicine Executives Make Significant Stock Purchases - TradingView
Prime Medicine CEO Acquires 125,000 Shares - TradingView
Biotech Stock Roundup: BMRN to Acquire INZY, NVAX Gains on Vaccine Approval & More - TradingView
Finance Watch: Prime, Kyverna, Allogene And More Announce Job Cuts - insights.citeline.com
Prime Medicine Announces Layoffs, CEO Transition: Retail Gets More Bullish - MSN
Prime Medicine Cuts Workforce By 25% In Strategic Shift - Finimize
CEO among 25% of staff out the door at cash-strapped Prime - The Pharma Letter
Prime Medicine (PRME) Sees Price Target Adjustment by JMP Securities | PRME Stock News - GuruFocus
This MongoDB Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday - Benzinga
Prime Medicine (PRME) Receives Downgrade from JP Morgan | PRME Stock News - GuruFocus
PRME: Prime Medicine Downgraded to Neutral by HC Wainwright & Co - GuruFocus
Prime Medicine downgraded to Neutral from Buy at H.C. Wainwright - TipRanks
Prime Medicine (PRME) Faces Downgrade Amid Strategic Shift | PRM - GuruFocus
Prime Medicine (PRME) Adjusts Strategy Amid Leadership Changes | - GuruFocus
Prime Medicine price target lowered to $6 from $10 at Citizens JMP - TipRanks
Prime Medicine, Inc.: Hold Rating Amid Strategic Restructuring and Long-term Uncertainty - TipRanks
Prime Medicine refocuses on liver disease, leadership changes By Investing.com - Investing.com South Africa
PRME Downgraded by JPMorgan Amid Strategic Shift | PRME Stock News - GuruFocus
Prime Medicine Inc (PRME) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Prime Medicine Inc 주식 (PRME) 내부자 거래
내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
---|---|---|---|---|---|---|---|
Liu David R. | 10% Owner |
Jun 16 '25 |
Buy |
1.49 |
21,000 |
31,196 |
20,198,945 |
Liu David R. | 10% Owner |
Jun 11 '25 |
Buy |
1.60 |
21,000 |
33,590 |
20,177,945 |
Brudnick Richard | Chief Business Officer |
May 20 '25 |
Buy |
1.19 |
20,000 |
23,790 |
20,000 |
LEE ANN L. | Chief Technical Officer |
May 21 '25 |
Buy |
1.13 |
100,000 |
113,000 |
100,000 |
Reine Allan | Chief Executive Officer |
May 21 '25 |
Buy |
1.18 |
125,000 |
147,150 |
125,000 |
자본화:
|
볼륨(24시간):